vTv Therapeutics

VTVT · NASDAQ

$27.85+$0.905 (+3.36%)TodayMarket closed · Oct 20, 5:00 PM ET

Prev close $26.94

VTVT analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $56.92 (+104.4% upside)

Low: $42.42
Now: $27.85
High: $70.35

Upgrades and downgrades

The latest rating actions, newest first

VTVT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 14, 2026	Maintains	Buy	$57.00	20%
HC Wainwright & Co.	Aug 6, 2026	Maintains	Buy	$45.00 → $42.00	27%
BTIG	Jul 16, 2026	Maintains	Buy	$49.00 → $57.00	20%
Evercore ISI Group	Mar 12, 2026	Initiates	Outperform	$44.00	0%
BTIG	Mar 11, 2026	Maintains	Buy	$49.00	20%
BTIG	Jan 27, 2026	Maintains	Buy	$40.00 → $49.00	20%
Roth Capital	Jan 23, 2026	Initiates	Buy	$58.00	17%
TD Cowen	Jan 5, 2026	Initiates	Buy	$67.00	42%
HC Wainwright & Co.	Dec 19, 2025	Maintains	Buy	$36.00 → $47.00	27%
BTIG	Nov 19, 2025	Initiates	Buy	$40.00	20%

The case for and against

Updated Oct 17, 2026

Bull case

vTv Therapeutics is viewed favorably because cadisegliatin addresses a major unmet need in type 1 diabetes: persistent hypoglycemia despite modern insulin delivery, with recent data showing this burden remains in about 54% of AID users. The lead Phase 3 CATT1 trial is fully enrolled with 166 patients randomized, is powered at 90% to detect a 30% reduction in Level 2/3 hypoglycemia, and has topline data expected in mid-2027, while prior SimpliciT1 results showed statistically significant HbA1c lowering and a 50% reduction in symptomatic hypoglycemia without a DKA signal. With FDA Breakthrough Therapy Designation, favorable KOL feedback, and a projected $840M peak sales opportunity, the company has a compelling late-stage clinical and commercial setup.

Bear case

vTv Therapeutics is fundamentally challenged by a high-risk, single-asset-heavy pipeline, where cadisegliatin’s commercial case still depends on proving both clinical benefit and regulatory acceptance in type 1 diabetes despite the persistent hypoglycemia burden in AID users. The company also faces meaningful execution and financial pressure, with 2Q26 operating expenses of $13.9M, 2Q26 EPS of ($1.05), and projected 2026 operating expenses of $53M, while cash and equivalents of $86.6M only support operations into 2028. Even if development succeeds, stiff T1D competition and reliance on third-party manufacturing add further uncertainty, making the risk/reward profile unattractive.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.